Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | STK25 | O00506 | 1/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | MUSK | O15146 | 1/20 | 0.38 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12554421 | 0.81 | NPC1 (0.34) | SYKBMPR1BCDC7PIK3CDPLK4 | |
| SCHEMBL12654383 | 0.81 | SYK (0.41) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL29671172 | 0.81 | SYK (0.41) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL22096128 | 0.81 | SYK (0.41) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL22192 | 0.81 | SYK (0.41) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL24156807 | 0.81 | SYK (0.41) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL5946341 | 0.79 | SYK (0.39) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL10187826 | 0.79 | SYK (0.39) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL14235384 | 0.79 | SYK (0.49) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B | |
| SCHEMBL15979058 | 0.79 | SYK (0.47) | SYKKDM4ESMN1; SMN2ALDH1A1BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021259208-A1 | TYK-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-12-30 | — | — | WO | disclosed |
| WO-2017137743-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137744-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
| EP-2252300-B1 | USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS | RIGEL PHARMACEUTICALS INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9040543-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8729087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8530466-B2 | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| US-8193197-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | SYK 42/4885KDM4E 1615/4885SMN1; SMN2 2525/4885 |
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | SYK 42/4885KDM4E 1615/4885SMN1; SMN2 2525/4885 |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | JAK1, JAK3, JAK2 | SYK 162/4885KDM4E 1600/4885SMN1; SMN2 4767/4885 |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885KDM4E 2840/4885SMN1; SMN2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.